Disparate Impact of Butyroyloxymethyl Diethylphosphate (AN-7), a Histone Deacetylase Inhibitor, and Doxorubicin in Mice Bearing a Mammary Tumor
Overview
Authors
Affiliations
The histone deacetylase inhibitor (HDACI) butyroyloxymethyl diethylphosphate (AN-7) synergizes the cytotoxic effect of doxorubicin (Dox) and anti-HER2 on mammary carcinoma cells while protecting normal cells against their insults. This study investigated the concomitant changes occurring in heart tissue and tumors of mice bearing a subcutaneous 4T1 mammary tumor following treatment with AN-7, Dox, or their combination. Dox or AN-7 alone led to inhibition of both tumor growth and lung metastases, whereas their combination significantly increased their anticancer efficacy and attenuated Dox- toxicity. Molecular analysis revealed that treatment with Dox, AN-7, and to a greater degree, AN-7 together with Dox increased tumor levels of γH2AX, the marker for DNA double-strand breaks and decreased the expression of Rad51, a protein needed for DNA repair. These events culminated in increased apoptosis, manifested by the appearance of cytochrome-c in the cytosol. In the myocardium, Dox-induced cardiomyopathy was associated with an increase in γH2AX expression and a reduction in Rad51 and MRE11 expression and increased apoptosis. The addition of AN-7 to the Dox treatment protected the heart from Dox insults as was manifested by a decrease in γH2AX levels, an increase in Rad51 and MRE11 expression, and a diminution of cytochrome-c release. Tumor fibrosis was high in untreated mice but diminished in Dox- and AN-7-treated mice and was almost abrogated in AN-7+Dox-treated mice. By contrast, in the myocardium, Dox alone induced a dramatic increase in fibrosis, and AN7+Dox attenuated it. The high expression levels of c-Kit, Ki-67, c-Myc, lo-FGF, and VEGF in 4T1 tumors were significantly reduced by Dox or AN-7 and further attenuated by AN-7+Dox. In the myocardium, Dox suppressed these markers, whereas AN-7+Dox restored their expression. In conclusion, the combination of AN-7 and Dox results in two beneficial effects, improved anticancer efficacy and cardioprotection.
Tarasenko N, Wilner H, Nudelman A, Kessler-Icekson G, Rephaeli A Pharmaceuticals (Basel). 2021; 14(12).
PMID: 34959644 PMC: 8706415. DOI: 10.3390/ph14121244.
Wang L, Wang L, Zhou X, Ruan G, Yang G Med Sci Monit. 2019; 25:2435-2444.
PMID: 30943187 PMC: 6459050. DOI: 10.12659/MSM.915194.
The Histone Deacetylase Inhibitor AN7, Attenuates Choroidal Neovascularization in a Mouse Model.
Dahbash M, Sella R, Megiddo-Barnir E, Nisgav Y, Tarasenko N, Weinberger D Int J Mol Sci. 2019; 20(3).
PMID: 30736437 PMC: 6387404. DOI: 10.3390/ijms20030714.
Moyal L, Goldfeiz N, Gorovitz B, Rephaeli A, Tal E, Tarasenko N Invest New Drugs. 2017; 36(1):1-9.
PMID: 28884410 DOI: 10.1007/s10637-017-0500-x.
Tarasenko N, Nudelman A, Rozic G, Cutts S, Rephaeli A Invest New Drugs. 2017; 35(4):412-426.
PMID: 28315153 DOI: 10.1007/s10637-017-0448-x.